Why GBIM is Up 40% in Four Days – and What to Do About It
Research - Our suggestion in November was to be long GBIM from below $6.00 in anticipation of data this quarter for GS-4774. We're up 75%. Here's what to do next.
PremiumAuthor Archives: Jake King
uniQure Fills in the Missing Piece with Bristol-Myers Collaboration
Research - Great news for our suggested uniQure (QURE) position – Bristol-Myers Squibb (BMY) is putting up $100 million upfront to partner with the European gene therapy developer … Continue Reading
Premium
Not so Tiny Anymore, Trillium Stocks the Coffers
Research - Trillium Therapeutics raised approximately $50 million in a secondary offering this week. The company is well-financed through 2016 and initial (critical) data on lead program, SIRPaFc. … Continue Reading
Premium
Your Guide to M&A Monday
Insights - Monday morning was jam-packed with deal flow in biotech. Here's a 60-second primer.
Read now
Biotech is Swooning. You Shouldn’t Be
Research - Our suggestion to take profits on some of our bigger winners late last week was well-timed. From the blow-off top (temporarily, at least) on Friday … Continue Reading
Read now
MEI Pharma’s Pracinostat Fails Latest Trial
Insights - A combination of MEI Pharma’s (MEIP) Pracinostat and the chemotherapy Vidaza (azacitidine) failed to improve remission rates compared to azacitidine alone in patients with Myelodysplastic Syndrome (MDS), … Continue Reading
Read now
Updating on a Number of Our Recent ‘Smid-Cap’ Picks
Research - With biotech where it is, we're suggesting taking profits on a number of our big winners in the past 6 months. Here are the details on CEMP, BLUE, TRIL, SAGE, MRNS, SGYP, GBIM, QURE, and TKMR.
Read now